Answer
Mekinist (trametinib dimethyl sulfoxide), combined with dabrafenib, is indicated for adults with advanced non-small cell lung cancer with a BRAF V600 mutation.
Sources for this answer
- Mekinist film-coated tabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 29Document updated
Sources checked